Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Early Phase clinical trial of DNA damage response inhibitors combined with 225Ac-DOTA-girentuximab (TLX252)

Next Previous
Trial Profile

Early Phase clinical trial of DNA damage response inhibitors combined with 225Ac-DOTA-girentuximab (TLX252)

Status: Planning
Phase of Trial: Phase 0

Latest Information Update: 29 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics (Primary) ; Ionising radiation emitters (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 29 Jun 2025 New trial record
  • 20 Jun 2025 According to Telix Pharmaceuticals media release, the company will present early phase data at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 - 24.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top